SMARCA4 and non-small cell lung carcinoma: 70-90% of SMARCA4 alterations were homozygous in NSCLC subtypes including the most common subtype, lung adenocarcinoma, with 15-40% representing truncating alterations (Supplementary Fig. 1d–e).